ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with AlgenScribe SAS (‘AlgenScribe’). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel…